Results 11 to 20 of about 1,700 (160)

Monoclonal Gammopathies of Clinical Significance-Scleromyxedema: A Case Report and Literature Review. [PDF]

Clin Case Rep
Scleromyxedema is an uncommon, chronic connective tissue disorder with an obscure etiology. It is distinguished by fibromyxoid skin lesions and elevated serum monoclonal immunoglobulin levels.
Liang S, Zeng J, Zhong P, Jia C, Zhang L.   +4 more
europepmc   +3 more sources

Scleromyxedema Managed With High-Dose Intravenous Immunoglobulin and Bortezomib-Dexamethasone: A Case Report. [PDF]

Case Rep Oncol Med
Scleromyxedema is a rare, chronic cutaneous mucinosis marked by widespread waxy papules and potential extracutaneous involvement. This case report discusses the management of a 48‐year‐old female diagnosed with scleromyxedema, who initially partially ...
Wijaya D, Hanson Z, Lau EK, Akhtari M.
europepmc   +3 more sources

Plasma cell-directed therapies induce profound clinical and durable responses in patients with severe or relapsed/refractory scleromyxedema. [PDF]

J Eur Acad Dermatol Venereol
Scleromyxedema (SM) is a rare skin disorder related to monoclonal gammopathy. High dose intravenous immunoglobulins (HDIVIg) are usually used as a frontline therapy with initial efficacy.
Theves F, Lahuna C, Mahévas T, Harel S, Royer B, Lemiale V, Brignier A, Parquet N, Jachiet M, Bouaziz JD, Elessa D, Arnulf B, Talbot A.   +12 more
europepmc   +3 more sources

Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 2, Scleromyxoedema and scleroedema [PDF]

Journal of the European Academy of Dermatology and Venereology, Volume 38, Issue 7, Page 1281-1299, July 2024.
The term 'sclerosing diseases of the skin' comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement ...
Knobler, Robert, Sunderkötter, Cord
core   +8 more sources

Therapeutic Plasma Exchange for the Symptomatic Treatment of Scleromyxedema: A Case Report and Literature Review

Journal of Clinical Apheresis, Volume 39, Issue 6, December 2024.
Scleromyxedema is a rare skin mucinosis often associated with systemic involvement and monoclonal gammopathy (MG). No formal recommendation for management with therapeutic plasma exchange (TPE) has been published due to rarity.
Matthew H Lanehart, Erika S Johnson, N. Aqui   +2 more
semanticscholar   +2 more sources

Assessment of Treatment Response in Patients With Scleromyxedema by the Double Modified Rodnan Skin Score

JEADV Clinical Practice, EarlyView.
Scleromyxedema (SMX) is a cutaneous mucinosis characterised by an abnormal accumulation of mucin in the skin and limited treatment options. Assessment of therapy response during treatment is challenging. Patients with SMX receiving high‐dose
Julia K. Winkler, A. Enk
semanticscholar   +2 more sources

Scleredema Associated With IgG/κ Monoclonal Gammopathy of Clinical Significance Successfully Treated With Daratumumab Monotherapy: A Case Report. [PDF]

EJHaem
ABSTRACT Background Cutaneous monoclonal gammopathy of clinical significance (MGCS) is rare and may present with scleredema‐like fibrosing skin disease. Case A 59‐year‐old man developed progressive induration of the upper body. Laboratory studies revealed an IgG/κ monoclonal protein, and skin biopsy showed dermal thickening with mucin deposition.
Marcolongo D, Bressan A, Zanatta E, Alaibac MSA, Gianesello I, Binotto G, Pavan L, Tos APD, Trentin L, Vianello F.   +9 more
europepmc   +2 more sources

Skin-Colored Papules on the Face and Chest of a Female Patient. [PDF]

Clin Case Rep
ABSTRACT Scleromyxedema is an unpredictable but progressive disease and can be lethal due to systemic involvement if not diagnosed timely. Hence, we require a keen observational clinical eye to diagnose the condition from its differentials, along with further research into treatment modalities to treat this condition.
Ghahartars M, Azimi SZ, Akbarzadeh Jahromi M, Namazi MR.   +3 more
europepmc   +2 more sources

Sclerosing diseases of the skin. [PDF]

J Dtsch Dermatol Ges
Summary Sclerosing skin diseases comprise a group of distinct dermatological conditions characterized by fibrotic changes that may severely impair patients’ quality of life. These conditions often present with cutaneous manifestations and, in some cases, may extend to extracutaneous tissues, potentially resulting in significant morbidity and mortality.
Kalantari Y, Meier K, Ghoreschi K, Kinberger M, Solimani F.   +4 more
europepmc   +2 more sources

Hyalase in Dermatology: Applications Beyond Filler Management. [PDF]

J Cosmet Dermatol
ABSTRACT Background Hyaluronic acid (HA) is a key extracellular matrix component in the skin. Hyaluronidase is an enzyme that breaks down HA into monosaccharides. The FDA has approved this enzyme for hypodermoclysis, drug absorption enhancement, and subcutaneous urography.
Hasanzadeh S, Farokh P, Hosseini GS, Abbasian M, Etesami I, Zaresharifi S, Dadkhahfar S.   +6 more
europepmc   +2 more sources